ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
62.98
-1.25 (-1.95%)
Jul 17, 2024, 4:00 PM EDT - Market closed

ANI Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 1997
Net Income
35.5517.15-49.52-42.79-22.556.09
Upgrade
Depreciation & Amortization
61.4261.0659.6547.2544.6444.61
Upgrade
Share-Based Compensation
23.2520.6514.610.4912.949.22
Upgrade
Other Operating Activities
-4.4118.47-57.56-11.82-19.76-14.29
Upgrade
Operating Cash Flow
115.8118.96-31.23.3215.2745.63
Upgrade
Operating Cash Flow Growth
1163.82%---78.24%-66.54%-31.97%
Upgrade
Capital Expenditures
2.41-8.87-8.130.09-6.14-6.64
Upgrade
Acquisitions
-9.64-9.64-7.61-105.58-62.19-20.91
Upgrade
Investing Cash Flow
-7.23-18.51-15.74-105.48-68.32-27.55
Upgrade
Share Issuance / Repurchase
81.8984.56-0.570.76-0.914.71
Upgrade
Debt Issued / Paid
-3-3-399.02-0.53-3.46
Upgrade
Other Financing Activities
-26.63-14.13-1.6324.81--
Upgrade
Financing Cash Flow
52.2667.44-5.13194.6-1.441.25
Upgrade
Net Cash Flow
160.84167.89-52.0792.43-54.4919.33
Upgrade
Free Cash Flow
118.22110.09-39.333.419.1339
Upgrade
Free Cash Flow Growth
18458.56%---62.61%-76.58%-36.42%
Upgrade
Free Cash Flow Margin
22.85%22.61%-12.43%1.58%4.38%18.88%
Upgrade
Free Cash Flow Per Share
6.096.05-2.420.270.763.24
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).